Results 31 to 40 of about 11,469 (180)

Hormone therapy (HT) in women with premature ovarian insufficiency or early menopause: Time to think of a new paradigm for healthy aging. A joint FIGO and IMS position paper

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Premature ovarian insufficiency (POI) and early menopause (EM) affect millions of women worldwide. Compared with normal menopause, they confer a longer duration of estrogen deficiency and are associated not only with a shorter lifespan, but with a reduced healthspan, owing to an increased risk of cardiovascular, skeletal, cognitive and ...
Chiara Benedetto, Suvarna S. Khadilkar, Rossella E. Nappi, Andrea R. Genazzani, Federica Frezet, Laura Cucinella, Hema Divakar, Panagiotis Anagnostis, Nick Panay   +8 more
wiley   +1 more source

Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment

, 2008
Claudia Gagnon, Vivien Li, Peter R EbelingDepartment of Medicine, University of Melbourne, Melbourne, AustraliaAbstract: As the population ages, the burden of osteoporosis in men is expected to rise.
Claudia Gagnon, Peter R Ebeling, Ebeling, PR, Vivien Li, Li, V, Gagnon, C   +5 more
core   +1 more source

Evaluation of Teriparatide for Treatment of Osteoporosis in Four Patients with Cystic Fibrosis: A Case Series

Case Reports in Endocrinology, 2014
Introduction. Bone disease is a common complication of cystic fibrosis (CF). To date, there have been no reports on the effectiveness of teriparatide, recombinant human parathyroid hormone, to treat CF-related bone disease. Case Presentation.
Oranan Siwamogsatham, Kelly Stephens, Vin Tangpricha   +2 more
doaj   +1 more source

Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment

Bone Reports, 2020
Introduction: Osteoporosis is one of the serious adverse effects associated with glucocorticoid therapy. Although bisphosphonates have been used for glucocorticoid-induced osteoporosis (GIO), some patients have shown an inadequate response. In such cases,
Yasuaki Hirooka, Yuji Nozaki, Asuka Inoue, Jinhai Li, Toshihiko Shiga, Kazuya Kishimoto, Masafumi Sugiyama, Koji Kinoshita, Masanori Funauchi, Itaru Matsumura   +9 more
doaj   +1 more source

Mind the Gap: Predictors of Osteoporosis Treatment Following Fragility Fracture in Parkinsonism

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Fracture risk is increased in Parkinson's yet this risk is often not addressed. Objectives Our objective was to study the extent to which osteoporosis was treated, and predictors of treatment in a large representative cohort with parkinsonism.
Katie C. Naylor, Emily J. Henderson, Emma Tenison   +2 more
wiley   +1 more source

Bone Health and Aging in Klinefelter Syndrome

Andrology, EarlyView.
ABSTRACT Klinefelter syndrome (KS) is typically diagnosed in young adults, but advances in prenatal testing have led to its recognition at a much earlier age. Conversely, diagnosis in late adulthood remains uncommon, but still occurs. Independently from the age at diagnosis, KS individuals now receive more accurate and tailored care management than in ...
Filippo Vignali, Daniele Renda Livraghi, Francesco Costantino, Sara De Vincentis, Vincenzo Rochira   +4 more
wiley   +1 more source

Denosumab discontinuation and fracture risk: getting the balance right

Internal Medicine Journal, EarlyView.
Abstract Denosumab is a highly effective therapy for osteoporosis. Since its approval by the Therapeutic Goods Administration (TGA) in 2010, use of denosumab has surged across Australia, delivering substantial fracture‐prevention benefits to tens of thousands of patients. However, stopping denosumab may lead to acute loss of bone with an increased risk
Albert S. Kim, Christian M. Girgis
wiley   +1 more source

Teriparatide Treatment in Patients with Severe Osteoporosis: Effects on Bone Mineral Density, Biochemical Parameters, Back Pain and Quality of Life

, 2014
Objective: To evaluate effects of teriparatide therapy on bone mineral density (BMD), biochemical parameters, back pain, and quality of life in patients with severe osteoporosis, who had long-term bisphosphonate treatment. Materials and Methods: Fifteen
Alev Çevikol, Gülşah Karataş, Özgür Zeliha Karaahmet, Aytül Çakcı, Eda Gürçay, Ebru Karaca Umay   +5 more
core   +1 more source

Teriparatide in fracture non-unions [PDF]

, 2015
Background: The use of teriparatide in the management of fracture disorders is poorly documented. This study aims to show that teriparatide administration may improve the healing process in patients with nonunions after open fixation of traumatic ...
Maffulli, Nicola, Coppola, Cristiano, Del Buono, Angelo   +2 more
core   +1 more source

Treatment of osteoporosis with teriparatide

, 2023
The aim of this study was to investigate the characteristics of postmenopausal women prescribed with teriparatide in Slovenia, during the first decade after its approval, and the predictors of bone mineral density (BMD) improvement with treatment.
Kocjan, Tomaž, Vidmar, Gaj, Orehek, Nina, Sabati Rajić, Antonela, Ostanek, Barbara, Jensterle Sever, Mojca, Janež, Andrej, Marc, Janja   +7 more
core   +1 more source